Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMQJHR7)

Drug Name
Indacaterol Drug Info
Synonyms
312753-06-3; QAB149; Arcapta; Onbrez; QAB-149; QAB 149; UNII-8OR09251MQ; 753498-25-8; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol Maleic Acid Salt; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; QAB-149; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; Indacaterol/mometasone
Cross-matching ID
PubChem CID
6918554
ChEBI ID
CHEMBL1095777
CAS Number
CAS 312753-06-3
TTD Drug ID
D03DJL
VARIDT Drug ID
DR00064
INTEDE Drug ID
DR0867
ACDINA Drug ID
D00326

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Cholesterol metabolism 1.79 1.47e-1 44/50 (88%) APOC1;PLTP;APOE;...
Steroid biosynthesis 1.79 7.66e-2 19/20 (95%) MSMO1;SQLE;NSDHL;...
Biosynthesis of unsaturated fatty acids 1.77 6.22e-2 21/27 (77.78%) SCD;ELOVL2;SCD5;...
ECM-receptor interaction 1.61 2.35e-1 80/88 (90.91%) SPP1;CD44;LAMC1;...
GnRH secretion 1.58 2.21e-1 60/64 (93.75%) SPP1;GPER1;GNAQ;...
Proximal tubule bicarbonate reclamation 1.52 3.04e-1 21/23 (91.3%) AQP1;CA2;GLUD1;...
Purine metabolism 1.51 2.83e-1 102/129 (79.07%) HPRT1;NT5E;PRPS2;...
Apelin signaling pathway 1.51 2.56e-1 117/137 (85.4%) SPP1;ACTA2;PLAT;...
PPAR signaling pathway 1.38 5.83e-1 66/74 (89.19%) FABP7;PLTP;HMGCS1;...
Pyrimidine metabolism 1.37 5.64e-1 40/56 (71.43%) NT5E;NME4;UCK2;...
Other glycan degradation 1.37 5.37e-1 13/18 (72.22%) HEXB;AGA;FUCA1
Renin secretion 1.34 5.61e-1 61/69 (88.41%) AQP1;PPP3CA;GNAS;...
Primary bile acid biosynthesis 1.34 5.29e-1 15/17 (88.24%) SLC27A5;CYP27A1;CYP7B1;...
IL-17 signaling pathway 1.34 5.04e-1 84/94 (89.36%) S100A8;CXCL5;MMP9;...
Salivary secretion 1.33 4.75e-1 76/93 (81.72%) LYZ;DMBT1;GNAS;...
Bladder cancer 1.32 4.79e-1 40/41 (97.56%) E2F2;MMP9;CXCL8;...
Synthesis and degradation of ketone bodies 1.27 6.36e-1 9/10 (90%) HMGCS1;ACAT2;BDH1;...
Other types of O-glycan biosynthesis 1.26 6.44e-1 29/47 (61.7%) GALNT7;GALNT12;RFNG;...
RNA polymerase 1.26 6.13e-1 23/31 (74.19%) POLR2D;POLR1C;POLR2I;...
Drug metabolism 1.24 6.63e-1 78/151 (51.66%) HPRT1;NME4;GSTM3;...
Terpenoid backbone biosynthesis 1.24 6.37e-1 18/22 (81.82%) HMGCS1;ACAT2;IDI1;...
Glycosaminoglycan degradation 1.21 7.33e-1 19/19 (100%) IDS;HEXB;HYAL2;...
Ribosome 1.21 7.04e-1 113/158 (71.52%) MRPS16;RPS26;RPL14;...
Nitrogen metabolism 1.21 6.87e-1 16/17 (94.12%) CA2;GLUD1;GLUL;...
Hematopoietic cell lineage 1.20 6.86e-1 90/99 (90.91%) CD44;DNTT;CD34;...
Thyroid hormone synthesis 1.20 6.62e-1 66/75 (88%) GNAS;TTR;GNAQ;...
Vitamin digestion and absorption 1.16 7.89e-1 17/24 (70.83%) SLC5A6;APOA1;APOB;...
Pentose phosphate pathway 1.16 7.79e-1 25/30 (83.33%) PRPS2;ALDOC;TKT;...
Glutamatergic synapse 1.15 7.94e-1 97/114 (85.09%) PPP3CA;GNAS;GNAQ;...
Peroxisome 1.14 7.88e-1 72/82 (87.8%) PXMP2;CRAT;SOD2;...
Viral protein interaction with cytokine and cytokine re... -1.46 1.37e-1 84/100 (84%) CXCL14;CCL8;CCL5;...
Shigellosis -1.46 1.37e-1 180/246 (73.17%) ACTR3;PLCG2;CSF2;...
Steroid hormone biosynthesis -1.49 1.30e-1 43/61 (70.49%) UGT2B15;SRD5A1;UGT2B17;...
Folate biosynthesis -1.49 1.30e-1 23/26 (88.46%) PTS;ALPP;FPGS;...
Colorectal cancer -1.50 1.29e-1 84/86 (97.67%) BCL2;DCC;MAPK1;...
NF-kappa B signaling pathway -1.50 1.33e-1 90/104 (86.54%) GADD45G;BLNK;ZAP70;...
Gastric cancer -1.51 1.27e-1 122/149 (81.88%) FZD4;GSK3B;PIK3R3;...
Acute myeloid leukemia -1.53 1.13e-1 66/67 (98.51%) MAPK1;KIT;PIK3R3;...
Caffeine metabolism -1.54 1.10e-1 5/6 (83.33%) NAT1
JAK-STAT signaling pathway -1.55 1.00e-1 146/162 (90.12%) IL12RB1;PIAS3;CSF2;...
Intestinal immune network for IgA production -1.56 1.03e-1 38/48 (79.17%) ICOS;HLA-DPA1;ITGB7;...
Malaria -1.56 1.08e-1 44/50 (88%) MET;MYD88;THBS4;...
Prolactin signaling pathway -1.56 1.07e-1 66/70 (94.29%) CGA;SOCS3;SOCS5;...
Cytokine-cytokine receptor interaction -1.56 1.10e-1 246/295 (83.39%) BMP5;LTA;IL7R;...
T cell receptor signaling pathway -1.57 1.10e-1 93/104 (89.42%) ICOS;ZAP70;CSF2;...
AGE-RAGE signaling pathway in diabetic complications -1.58 1.00e-1 97/100 (97%) PIK3CA;THBD;NOS3;...
Cytosolic DNA-sensing pathway -1.58 1.06e-1 52/63 (82.54%) TBK1;POLR3F;PYCARD;...
Inflammatory bowel disease -1.58 1.11e-1 58/65 (89.23%) RORA;HLA-DOA;TNF;...
TGF-beta signaling pathway -1.59 1.12e-1 81/94 (86.17%) PPP2CA;INHBE;RPS6KB2;...
Proteoglycans in cancer -1.59 1.18e-1 172/205 (83.9%) PPP1R12B;PLCG2;ERBB3;...
Fatty acid degradation -1.60 1.15e-1 40/43 (93.02%) ECHS1;ALDH2;ADH1B;...
Chronic myeloid leukemia -1.61 1.13e-1 72/76 (94.74%) E2F3;PIK3CA;CTBP1;...
Allograft rejection -1.61 1.24e-1 32/38 (84.21%) HLA-DPB1;CD86;HLA-A;...
Legionellosis -1.65 9.61e-2 51/57 (89.47%) RAB1A;PYCARD;MYD88;...
Graft-versus-host disease -1.67 8.60e-2 32/42 (76.19%) CD80;HLA-G;FASLG;...
Salmonella infection -1.67 9.67e-2 198/249 (79.52%) ACTR2;MAP2K4;ARPC2;...
Systemic lupus erythematosus -1.68 1.07e-1 45/135 (33.33%) C6;HLA-DOA;TNF;...
Ascorbate and aldarate metabolism -1.69 1.11e-1 15/30 (50%) RGN;ALDH1B1;UGT2A3;...
Viral myocarditis -1.71 1.12e-1 53/60 (88.33%) HLA-DPB1;CD86;HLA-A;...
Proteasome -1.72 1.23e-1 44/46 (95.65%) PSMF1;PSME3;PSMD3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 2.22uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H